Dr. Muhammad Sadeqi Nezhad earned his Ph.D. in Translational Biomedical Science from the Clinical and Translational Science Institute at the University of Rochester Medical Center, New York. He conducted his doctoral research at the Wilmot Cancer Institute, an NCI-designated cancer center ranked among the top cancer centers in the United States.
Dr. Sadeqi Nezhad is a cancer scientist and inventor focused on the development of next-generation therapeutic platforms for cancer treatment. His work centers on designing innovative therapeutic approaches and technology-driven platforms, including antibody- and RNA-based therapeutics. He has invented multiple therapeutic candidates and is the inventor on several patents and patent applications.
His core expertise lies in gene and protein editing technologies, reverse-engineering, biological drug development, designing and executing translational experiments and protocol in cancer field. Besides, He founded KAHF Biotech, Inc., to open a new avenue for prevention and treatment of metastatic tumor cells.
As the CEO and Founder of KAHF Biotech, Inc., I am responsible for setting the strategic vision and guiding the company’s scientific and business direction. I lead efforts to secure funding, build key partnerships, and translate our innovative research into viable clinical solutions. My role involves making high-stakes decisions, aligning our team around clear goals, and fostering a mission-driven culture focused on advancing impactful therapies for pancreatic cancer and beyond.
His Areas of Expertise Are:
- Designing and developing CRISPR/Cas9 Technology for Knock-In, Knock-out, and Knock-down
- Designed and developed CRISPR/Cas13 and CRISPR Activation (SUNTAG) Systems
- Viral production (Lentivirus, Retrovirus, and Adeno Associated Virus)
- Designing short/small hairpin RNA (shRNA) for lentivirus
- Biotin Ligase or BioID Technology, a Tool for Protein-Proximity Labeling in Living Cells
- Degron Technology for discovering and validating new disease targets
- Different Molecular Cloning Techniques
- Electroporation, Transfection, and Transduction
- Orthotopic Tumor Model Development
- Novel Chimeric Antigen Receptor (CAR) Plasmids Development
- Expert in Recombinant Monoclonal Antibodies Development & Designing
- Expert in therapeutic Dicer Substrate siRNA Development & Designing
- Expert in designing Antibody Drug Conjugate (ADCs), Antibody Oligonucleotide Conjugate (AOC), and Degrader Antibody Conjugate (DAC) Technologies
